By Fineline Cube 
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced a landmark Technology Transfer and Supply Agreement with Fundação Oswaldo Cruz‑Bio‑Manguinhos (FZ) and BIOMM S.A. as part of Brazil’s Production Development Partnerships Program (PDP). The deal includes a separate Supply Framework Agreement with BIOMM valued at no less than 3 billion RMB.
How the Agreement Works
| Step | Action | Outcome |
|---|---|---|
| 1 | Gan Lee transfers insulin glargine technology to FZ | FZ gains full manufacturing capability for the insulin |
| 2 | Gan Lee supplies insulin glargine injections and APIs to BIOMM | BIOMM becomes the primary distributor |
| 3 | BIOMM relays filling technology to FZ | FZ can produce both injections and insulin pens |
| 4 | FZ commits to purchase agreed volumes from BIOMM for 10 years | Guarantees a stable, long‑term supply chain |
Strategic Significance
- Public‑Health Impact – The PDP is Brazil’s flagship initiative to secure essential medicines through technology transfer and public‑market procurement.
- Local Manufacturing – The partnership creates a fully integrated local manufacturing ecosystem for insulin glargine, reducing dependence on imports.
- Economic Scale – A 3 billion RMB contract underscores the program’s financial commitment to long‑term affordability.
Market Outlook
- Growing Demand – Brazil’s diabetes burden is projected to exceed 10 million patients by 2030, creating a robust market for long‑acting insulins.
- Competitive Advantage – Gan Lee’s early entry into the Brazilian PDP positions it ahead of rivals that still rely on external suppliers.
- Future Expansion – The successful PDP model may serve as a blueprint for similar technology‑transfer deals in other emerging markets.-Fineline Info & Tech